The estimated Net Worth of Ajay Gupta is at least $2.08 million dollars as of 13 August 2015. Ajay Gupta owns over 5,000 units of Rockwell Medical Inc stock worth over $1,339,335 and over the last 15 years he sold RMTI stock worth over $0. In addition, he makes $736,730 as Chief Scientific Officer at Rockwell Medical Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ajay Gupta RMTI stock SEC Form 4 insiders trading
Ajay has made over 2 trades of the Rockwell Medical Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of RMTI stock worth $58,100 on 13 August 2015.
The largest trade he's ever made was exercising 13,000 units of Rockwell Medical Inc stock on 1 October 2014 worth over $87,620. On average, Ajay trades about 857 units every 15 days since 2009. As of 13 August 2015 he still owns at least 326,667 units of Rockwell Medical Inc stock.
You can see the complete history of Ajay Gupta stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ajay Gupta biography
Dr. Ajay Gupta M.D. serves as Chief Scientific Officer of the Company. He has served as the Company’s Chief Scientific Officer since June 2009. Before joining the Company, Dr. Gupta spent the prior seven years as an associate professor of medicine at UCLA and Charles Drew University Schools of Medicine, Los Angeles, CA, where he had an active nephrology practice. Prior to that, Dr. Gupta served on the faculties of Henry Ford Hospital, Detroit, MI, University of Alabama, Birmingham, State University of New York, Syracuse and Washington University, St. Louis. Dr. Gupta also completed a clinical fellowship in Nephrology from Wayne State University, Detroit, Michigan and a research fellowship in Nephrology from Washington University, St. Louis, Missouri. Dr. Gupta, who is the founder and chairman of the Indian Society for Bone and Mineral Research, earned his MBBS degree and completed his residency in Internal Medicine from All India Institute of Medical Sciences, New Delhi.
What is the salary of Ajay Gupta?
As the Chief Scientific Officer of Rockwell Medical Inc, the total compensation of Ajay Gupta at Rockwell Medical Inc is $736,730. There are 1 executives at Rockwell Medical Inc getting paid more, with Raymond Pratt having the highest compensation of $965,874.
How old is Ajay Gupta?
Ajay Gupta is 62, he's been the Chief Scientific Officer of Rockwell Medical Inc since 2009. There are 6 older and 9 younger executives at Rockwell Medical Inc. The oldest executive at Rockwell Medical Inc is Dr. Russell H. Ellison M.Sc., M.D., MSc., 73, who is the Pres, CEO & Director.
What's Ajay Gupta's mailing address?
Ajay's mailing address filed with the SEC is 2505 SEASCAPE DRIVE, , LAS VEGAS, NV, 89128.
Insiders trading at Rockwell Medical Inc
Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm... et Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.
What does Rockwell Medical Inc do?
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
What does Rockwell Medical Inc's logo look like?
Complete history of Ajay Gupta stock trades at Rockwell Medical Inc
Rockwell Medical Inc executives and stock owners
Rockwell Medical Inc executives and other stock owners filed with the SEC include:
-
Raymond Pratt,
Chief Development Officer -
Ajay Gupta,
Chief Scientific Officer -
Dr. Russell H. Ellison M.Sc., M.D., MSc.,
Pres, CEO & Director -
Dr. Raymond Dennis Pratt FACP, M.D.,
Chief Devel. Officer -
Russell L. Skibsted M.B.A.,
Exec. VP, CFO & Chief Bus. Officer -
John Cooper,
Independent Director -
Mark Ravich,
Independent Director -
John McLaughlin,
Independent Chairman of the Board -
Robert Radie,
Independent Director -
Marc Hoffman,
Chief Medical Officer -
Michael DeYoung,
Vice President - Operations -
Paul McGarry,
Principal Accounting Officer, Vice President, Corporate Controller -
Jim McCarthy,
Senior Vice President - Corporate and Business Development -
Russell Skibsted,
Executive Vice President, Chief Financial Officer and Chief Business Officer -
Russell Ellison,
President, Chief Executive Officer, Director -
David J. Kull,
Sec. -
Dr. Marc L. Hoffman,
Chief Medical Officer -
Timothy T. Chole,
Sr. VP of Sales & Marketing -
Megan C. Timmins,
Sr. VP, Gen. Counsel & Corp. Sec. -
Paul E. McGarry,
VP, Corp. Controller & Principal Accounting Officer -
Tim Chole,
VP of Marketing -
Anne Boardman,
VP of Sales and Strategic Accounts -
James A. McCarthy,
Sr. VP of Bus. & Corp. Devel. -
Michael Costello,
Gen. Counsel -
David S.Rbi Private Investm...,
-
Patrick J Bagley,
Director -
Ronald D Boyd,
Director -
Robin L Smith,
Director -
Kenneth L Holt,
Director -
Allen Nissenson,
Director -
Stuart M Paul,
Chief Executive Officer -
Brothers, Inc.Richmond Davi...,
-
Benjamin Wolin,
Director -
Lisa N Colleran,
Director -
Mark H Ravich,
Director -
David Kull,
Principal Accounting Officer -
David S.Rbi Private Investm...,
-
Angus W. Smith,
Chief Financial Officer -
David S.Rbi Private Investm...,
-
Mark Strobeck,
President and CEO -
David A Hagelstein,
10% owner -
Annamaria T Kausz,
VP of Drug Development -
Robert L Chioini,
Chairman, President and CEO -
Richard C Yocum,
VP - Clin. Dev. & Med. Affairs -
Thomas E Klema,
Vice President, CFO -
Megan C. Timmins,
EVP, CLO and Secretary -
David S.Rbi Private Investm...,
-
Joan Lau,
Director -
Jesse Neri,
SVP, FINANCE